Zobrazeno 1 - 8
of 8
pro vyhledávání: '"António Melo Gouveia"'
Autor:
António Melo Gouveia
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 4, Iss 2 (2012)
The most recent data about stability of fligrastim biossimilar (“Nivestim™), as made available by the marketing authorization holder, is analyzed with a focus on different storage conditions and impact on real life use, both for patients and heal
Externí odkaz:
https://doaj.org/article/512a4c23ecbc42a18a9e20616abbe902
Autor:
Ana Paula Carrondo, António Melo Gouveia, Clementina Varela, Daniel Pereira da Silva, Florbela Braga, Isabel Fernandes, João Oliveira, Jorge Espírito Santo, José Casanova, Maria José Pontes, Marta Soares, Paulo Tavares, Rodrigo Reis
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 4, Iss 1 (2012)
A presente reunião de reflexão teve como objectivo debater aspectos referentes à realidade portuguesa no âmbito do diagnóstico e tratamento de doentes com sarcomas. Durante a reunião foram apresentados dados relativos à doença, foram identifi
Externí odkaz:
https://doaj.org/article/5405aa5966a44fdb82b794adca148baf
Autor:
Julian Perelman, Filipa Duarte-Ramos, António Melo Gouveia, Luis Pinheiro, Francisco Ramos, Sabine Vogler, Céu Mateus
Background There is limited evidence on within-country discrepancies in biosimilar uptake. This study analyzes differences in timing and diffusion of biosimilar uptake across Portuguese NHS hospitals and explores possible determinants. Research desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c87f8f4eaf2be9136704aa16990626b1
https://doi.org/10.1080/14737167.2023.2146579
https://doi.org/10.1080/14737167.2023.2146579
Autor:
Dinis Mateus, Joana Marto, Patrícia Trindade, Humberto Gonçalves, Ana Salgado, Paula Machado, António Melo-Gouveia, Helena M. Ribeiro, António J. Almeida
Publikováno v:
Pharmaceutics, Vol 11, Iss 2, p 76 (2019)
The use of morphine applied topically to painful wounds has potential advantages, such as dose reduction, fewer side effects and compound formulations, have been proposed for this purpose. Given the potential high impact of drug product quality on a
Externí odkaz:
https://doaj.org/article/b8a7a640461f4943a691df8013d5d6f3
Publikováno v:
National poster prize winners.
Background and importance Safe handling and dispensing of cytotoxic drugs in outpatient setting are of growing concern in hospital pharmacy. However, surface contamination studies mainly focus on the preparation areas. As oral therapy gains significa
Autor:
Luís D'Orey, Rui Araújo, Sílvia Virginia Pereira da Silva, Ana Harfouche, António Melo Gouveia, João Leal de Faria, Maria Betânia Lacerda
Publikováno v:
Acta Médica Portuguesa; v. 30, n. 11 (2017): Novembro; 762-768
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Introducao: O cancro de mama e a segunda doenca oncologica mais comum no mundo. Com o proposito de estudar o novo financiamento por patologia – cancro de mama – implementado no Instituto Portugues de Oncologia de Lisboa Francisco Gentil, foram an
Autor:
M Fernanda Sachse, H Gonçalves, Alice Gelpi, António Melo Gouveia, Ana María Salgado, D Mateus, Paula Machado, Helena Ribeiro, Joana Marto, P Trindade
Publikováno v:
European Journal of Hospital Pharmacy. 25:43-47
Background Primary cutaneous lymphomas (extranodular non-Hodgkin lymphomas) are rare (incidence 1:100 000). Mycosis fungoides is the most common cutaneous T-cell lymphoma (CTCL) subtype. Treatment options are based on the diagnosis and the stage of t
Autor:
Joana Marto, António Melo-Gouveia, D Mateus, Helena Ribeiro, P Trindade, António J. Almeida, Ana Salgado, H Gonçalves, Paula Machado
Publikováno v:
Pharmaceutics, Vol 11, Iss 2, p 76 (2019)
Pharmaceutics
Volume 11
Issue 2
Pharmaceutics
Volume 11
Issue 2
The use of morphine applied topically to painful wounds has potential advantages, such as dose reduction, fewer side effects and compound formulations, have been proposed for this purpose. Given the potential high impact of drug product quality on a